Business Wire

Aceto Consolidates Acquisition of Six Manufacturers, Strengthening Its Unique Hybrid Model that Provides Major Supply Chain Benefits to Customers

Share

Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, today reported it has consolidated and integrated its six manufacturing-related acquisitions to achieve a hybrid manufacturing/distribution model providing key benefits to its customers in high-growth end markets including pharmaceuticals, biopharmaceuticals, vaccines, nutraceuticals, agriculture, cosmetics and specialty chemicals. These developments are especially timely as the Covid-19 pandemic continues to show the fragility of global supply chains, requiring companies to rethink their current strategies and focus on achieving supply chain resilience and security.

“Over seven decades, Aceto built a leading position as a value-added global ingredients supplier sourcing thousands of specialty ingredients to customers demanding quality and reliability,” said Gilles Cottier, Chief Executive Officer of Aceto. “In the past few years, we have moved aggressively to complement and expand these capabilities by adding high quality manufacturing operations across key strategic global markets. Our core competencies and operations now span three continents, as well as the entire R&D and product development/manufacturing spectrum.”

Aceto’s operations in 10 countries handle more than 3,000 products, including reagents and process aids, intermediates, active pharmaceutical ingredients (APIs) and excipients. Its capabilities encompass R&D, production, quality assurance, supply chain management, global sourcing, Good Manufacturing Practices (GMP) grade manufacturing, and regulatory and quality compliance. The company’s expert procurement teams, which are strategically located in centers of excellence in key regions across Asia, Europe and North America, represent a major resource for Aceto’s customers. They are now strengthened by having access to Aceto’s own captive GMP manufacturing resources in addition to rigorously selected external suppliers.

Mr. Cottier added, “Our hybrid model and broad competencies provide agility and choice to our customers. This allows them to more rapidly develop and commercialize innovative products while assuring a diversified, flexible and dependable supply chain, whose critical importance has been so dramatically highlighted by the ongoing pandemic. In this regard, we are especially proud of our industry-leading on-time in-full rate. We intend to continue to invest in advanced systems and additional targeted acquisitions to further integrate and augment our operations and provide ever greater capabilities and value to our diverse and growing customer base.”

Prior to the Covid-19 pandemic, Aceto had recognized the growing demand in the pharmaceutical and biopharmaceutical sectors for high-quality critical GMP excipients and raw materials, and as part of its growth strategy it expanded its manufacturing footprint by acquiring six companies in less than 18 months, increasing its global R&D and GMP manufacturing capabilities. The acquired companies include:

  • A&C - a global GMP manufacturer of specialty excipients, buffers, process solutions and raw materials for the biopharmaceutical sector.
  • A&C Bio Buffer- a leading GMP manufacturer of custom buffer and chemical blend products used in the manufacturing of biopharmaceutical drug products and vaccines.
  • Cascade Chemistry - a manufacturer of APIs, regulatory starting materials and advanced intermediates, enabling Aceto to provide customers enhanced support throughout the drug development process and greater access to expanded North American manufacturing.
  • Finar - a leading manufacturer, supplier and distributor of pharmaceutical excipients, lab chemicals, aquaculture inputs and food grade additives.
  • Islechem - a specialty chemical manufacturing organization that also provides contract research and development, analytical services and technical support services.
  • Syntor Fine Chemicals - a fine chemical manufacturer offering process development and R&D services.

About Aceto

Aceto is a leading global manufacturer and supplier of differentiated specialty ingredients to life sciences and advanced technology end markets. With business operations in 10 countries, Aceto manufactures and supplies over 3,000 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural and specialty chemical industries. In just two years Aceto has made six acquisitions of firms with expanded manufacturing, R&D and portfolio offerings, transforming the company into a worldwide supplier of critical raw materials with a robust manufacturing footprint. Aceto’s global operations, including a significant presence on the ground in China, India, Europe and North America, enable the company’s deep worldwide sourcing and regulatory capabilities. Aceto is well positioned to innovate new solutions, ensure quality and customize products to meet customers’ specific needs. Its expanded capabilities and decades of global sourcing expertise are especially valuable now that supply chain management is a critical strategic issue for companies worldwide. For more information visit aceto.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Debra Harrsch
Brandwidth Solutions
dharrsch@brandwidthsolutions.com
(215) 997-8575

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kao Releases the Kao Integrated Report 202513.6.2025 05:00:00 EEST | Press release

Kao Corporation (TOKYO:4452) has published the Kao Integrated Report 2025 on its website, offering shareholders, investors, and all stakeholders with a comprehensive overview of the company’s initiatives and strategic direction. Kao Integrated Report 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609991718/en/ The cover visual represents our “moonshot.” It embodies our commitment to achieving the ambitious goal of a sustainable society for future generations. To achieve its Mid-term Plan “K27,” Kao aims to become a unique presence indispensable to someone in the world and is advancing its Global Sharp Top strategy. In FY2024, Kao exceeded its targets by strengthening Return on Invested Capital (ROIC) management and strategically investing to build stronger, more robust businesses. This report offers an in-depth look at Kao’s progress under K27, highlighting how Kao’s dedicated employees—through the Global Sharp Top s

Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl

Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 22:30:00 EEST | Press release

Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal, but a core driver of innovation. Key milestones include a near-complete transition to natural refrigerants

Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 21:45:00 EEST | Press release

Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of European enterprises, providing a framework for high performance in even the most complex, secure environments. “With about 6 million developers across Europe, users deserve infrastructure that meets them where they are,” said Varun Mohan, CEO of Windsurf. “The demand for secure AI-powered development is undeniable and by launching this GPU cluster, we aim to b

Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 20:00:00 EEST | Press release

Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization journey, allowing developers to focus on building engaging games, not commerce infrastructure. This SDK connects three

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye